For advanced NSCLC harboring EGFR activating mutations, EGFR TKIs treatment provided higher response rate (60–80%), and significantly extended progression-free survival (PFS)5, 7, 19. This evidence concerns the gene EGFR and non-small cell lung carcinoma.